[1] 李璘, 肖志坚. 成人难治/复发性急性淋巴细胞白血病的治疗现况 [J]. 国际输血及血液学杂志 2006.doi:10.3760/cma.j.issn.1673-419X.2006.05.015
[2] Litzow MR. [J]. Blood reviews 2004.
[3] Kantarjian H, Thomaa D, O'Brien S. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(Hyper-CVAD), a dose intenaive regimen, in adult acute lymphocytic leukemia [J]. Cancer 2004, 101(12).
[4] Kolb EA, Steinherz PG. [J]. Leukemia: Official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003.
[5] Kantarjian HM, Waiters RS, Keating M J. Experience with vincriatine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia [J]. Cancer 1989, 64(01).
[6] Ettinger LJ, Kurtzberg J, Voute PA. An open label, multicentre study of polyethylene glycol l-asparaginase for the treatment of acute lymphoblaatic leukemia [J]. CANCER 1995, 75(05).
[7] Koskela K, Pelliniemi T, Remesk. VAD regimen in the treatment of resistant multiple myeloma:slow or faat infusion [J]. Leukemia and Lymphoma 1993, 10(4-5). |
